Risk factors
MeiraGTx Holdings (MGTX) risk factors
Item 1A of every MeiraGTx Holdings plc 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors78 risks10 new5 dropped19 reworded
MeiraGTx continues to accumulate net losses, reaching an accumulated deficit of approximately $816.2 million as of December 31, 2025. The company added new risks covering artificial intelligence adoption, potential biosimilar competition, and environmental liabilities. Clinical and regulatory hurdles for its gene therapy platform and third-party dependencies remain central.
Filed Mar 30, 2026 - FY2024 10-K risk factors73 risks
MeiraGTx faces ongoing operating losses, relies heavily on milestone payments from Johnson & Johnson, and requires additional capital to fund clinical development.
Filed Mar 13, 2025